Evidence map›Paper›PMID 22547203›Full record

ReviewCurrent rheumatology reports2012

Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?

William Stohl

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Lupus nephritis: the evolving role of novel therapeutics.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2014
    Review
  15. Article
  16. Review
  17. B-lymphocyte lineage cells and the respiratory system.The Journal of allergy and clinical immunology · 2013
    Review
  18. Cellular targeting in autoimmunity.Current allergy and asthma reports · 2012
    Review
  19. Therapeutic effects of a novel BAFF blocker on arthritis.Signal transduction and targeted therapy
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

William StohlDivision of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033, USA. stohl@usc.edu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug, belimumab, is a monoclonal antibody that neutralizes the B-cell survival factor, B-lymphocyte stimulator (BLyS). Although belimumab has demonstrated a very favorable safety profile, many SLE patients have failed to clinically improve from belimumab therapy. Three additional BLyS antagonists (atacicept, blisibimod, tabalumab) are currently undergoing clinical testing. These antagonists subtly differ from belimumab in their biologic targets, and each is administered through a route (subcutaneous) that differs from the route through which belimumab is currently delivered (intravenous). Whether these differences will have meaningful consequences for efficacy and safety remains to be determined.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB-Cell Activating FactorHumansImmunologic FactorsLupus Erythematosus, SystemicMiceMolecular Targeted TherapyRecombinant Fusion ProteinsAMG623 peptibodyAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB-Cell Activating FactorbelimumabImmunologic FactorsRecombinant Fusion ProteinstabalumabTACI receptor-IgG Fc fragment fusion proteinTNFSF13B protein, human

Identifiers

PMID22547203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.